These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 18676233)

  • 21. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
    J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
    Innominato PF; Giacchetti S; Moreau T; Bjarnason GA; Smaaland R; Focan C; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Poncet A; Spiegel D; Lévi F;
    Cancer; 2013 Jul; 119(14):2564-73. PubMed ID: 23633399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
    Kato K; Inaba Y; Tsuji Y; Esaki T; Yoshioka A; Mizunuma N; Mizuno T; Kusaba H; Fujii H; Muro K; Shimada Y; Shirao K
    Jpn J Clin Oncol; 2011 Jan; 41(1):63-8. PubMed ID: 20819832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer.
    Koca D; Ünal OÜ; Öztop I; Yılmaz U
    Turk J Gastroenterol; 2014 Apr; 25(2):198-204. PubMed ID: 25003682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion.
    Mattioli R; Lippe P; Recchia F; Massacesi C; Imperatori L; De Filippis S; Rosselli M; Gattafoni P; Casadei V; Consales D
    Anticancer Res; 2001; 21(1A):489-92. PubMed ID: 11299785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
    J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
    Laudani A; Gebbia V; Leonardi V; Savio G; Borsellino N; Cusimano MP; Calabria C; Stefano R; Agostara B
    Anticancer Res; 2004; 24(2C):1139-42. PubMed ID: 15154638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
    Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
    Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
    Minami K; Kameda A; Tsutani Y; Suzuki T; Miyahara E; Noso Y
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):573-7. PubMed ID: 17431362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 38. Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer.
    Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Biondi E; Massa E; Mantovani G
    Anticancer Res; 2004; 24(3b):1935-40. PubMed ID: 15274380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
    Mohammad HA; Magdy FM; Mahmoud OM
    Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
    Cai X; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):39-43. PubMed ID: 22490854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.